论文部分内容阅读
目的研究分析阿托伐他汀强化治疗短期内对急性冠状动脉(冠脉)综合征血浆B型尿钠肽(BNP)及血脂的早期影响。方法 84例急性冠脉综合征患者,采用随机数字表法分为观察组和对照组,各42例。两组患者均进行基础治疗,在此基础上,观察组患者进行阿托伐他汀强化治疗,对照组患者进行阿托伐他汀常规治疗。对两组的治疗效果进行比较分析。结果观察组患者治疗后总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)水平与对照组比较差异无统计学意义(P>0.05);观察组治疗后血浆BNP水平为(418.46±105.52)pg/ml,与对照组的(539.65±110.17)pg/ml比较差异有统计学意义(P<0.05)。结论阿托伐他汀强化治疗短期内能降低急性冠脉综合征患者的血浆BNP水平,且对该类患者血脂并无显著影响,值得临床推广与借鉴。
Objective To investigate the early effects of atorvastatin on plasma B-type natriuretic peptide (BNP) and serum lipids in patients with acute coronary syndrome (ACS) in the short term. Methods Eighty-four patients with acute coronary syndrome were divided into observation group and control group by random number table method, with 42 cases in each. On the basis of this, the patients in the observation group were treated with atorvastatin and the patients in the control group were given routine treatment with atorvastatin. The two groups of treatment were compared. Results There was no significant difference in total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) between the observation group and the control group after treatment (P> 0.05) Plasma BNP level in the observation group was (418.46 ± 105.52) pg / ml, which was significantly lower than that in the control group (539.65 ± 110.17 pg / ml) (P <0.05). Conclusions Atorvastatin can shorten the plasma BNP level in acute coronary syndrome patients in short term, and has no significant effect on the blood lipid level of these patients, which is worthy of clinical promotion and reference.